Healthcare Services

Upadacitinib Market Growth Expected to Reach $2.89 Billion by 2030 with 14% CAGR

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Upadacitinib Market Evolve From 2026 To 2030?

The upadacitinib market has experienced rapid expansion in recent years. It is projected to increase from $1.5 billion in 2025 to $1.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. The market’s past growth can be attributed to several factors, including the rising prevalence of rheumatoid arthritis, the limitations of conventional DMARDs, an increasing need for targeted therapies, the presence of oral treatment choices, and the broadening of specialty care services.

The upadacitinib market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $2.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.0%. This projected growth during the forecast period is fueled by several factors, including a rise in clinical approvals for novel indications, a heightened emphasis on personalized autoimmune therapies, the enlargement of oral immunotherapy pipelines, increased funding for inflammatory disease research, and a greater uptake of sophisticated small molecule drugs. Key trends characterizing this period encompass the growing adoption of JAK inhibitor treatments, a rising inclination towards oral targeted therapies, the expanding utilization of small molecule immunomodulators, a broader spectrum of autoimmune disease indications, and an intensified commitment to long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21311&type=smp

What Major Drivers Are Influencing Demand In The Upadacitinib Market?

The increasing occurrence of autoimmune conditions is anticipated to fuel the expansion of the upadacitinib market in the future. These diseases involve the immune system erroneously attacking the body’s healthy cells, perceiving them as external threats. Factors contributing to the prevalence of autoimmune diseases include genetic susceptibility, environmental catalysts, and alterations in lifestyle and immune system function. Upadacitinib addresses autoimmune diseases by specifically targeting and inhibiting JAK1, thereby effectively diminishing inflammation and adjusting the immune response in conditions like rheumatoid arthritis and psoriatic arthritis. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that in 2025, approximately 212,136 males and 362,137 females are estimated to suffer from rheumatoid arthritis (RA). These figures are projected to increase by 2040 to roughly 280,040 males and 479,828 females. Consequently, the growing occurrence of autoimmune diseases is a key factor propelling the expansion of the upadacitinib market.

Which Segment Areas Are Covered In The Upadacitinib Market Analysis?

The upadacitinib market covered in this report is segmented –

1) By Drug Classes: Janus Kinase Inhibitors, Antirheumatic Agents, Small Molecule Drugs

2) By Application: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease

3) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Janus Kinase Inhibitors: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors, TYK2 Inhibitors

2) By Antirheumatic Agents: Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic DMARDs, Conventional Synthetic DMARDs

3) By Small Molecule Drugs: Oral Small Molecule Drugs, Topical Small Molecule Drugs

What Key Trends Are Influencing The Development Of The Upadacitinib Market?

Key companies operating in the upadacitinib market are concentrating on developing innovative products, such as oral Janus kinase (JAK) inhibitors, to expand therapeutic options for autoimmune conditions. Oral Janus kinase inhibitors are small-molecule drugs that obstruct Janus kinase enzymes to suppress excessive immune activation and inflammation, thereby effectively treating autoimmune and inflammatory diseases. For instance, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) had received European Commission approval for treating moderately to severely active Crohn’s disease. This oral formulation allows for once-daily administration, improving both convenience and adherence for patients. The oral delivery method provides a quicker onset of action compared to traditional treatments, making it simpler for patients to follow their prescribed treatment plans.

Which Global Companies Are Actively Competing In The Upadacitinib Market?

Major companies operating in the upadacitinib market are AbbVie Inc, Pfizer Inc, Eli Lilly and Company, Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Ltd, Astellas Pharma Inc, AstraZeneca PLC, Gilead Sciences Inc, Teva Pharmaceutical Industries Ltd, Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co Ltd, Galapagos NV, UCB SA, Daiichi Sankyo Company Ltd, Horizon Therapeutics plc, Regeneron Pharmaceuticals Inc.

Read the full upadacitinib market report here:

https://www.thebusinessresearchcompany.com/report/upadacitinib-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Upadacitinib Market?

North America was the largest region in the upadacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the upadacitinib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Upadacitinib Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21311&type=smp

Browse Through More Reports Similar to the Global Upadacitinib Market 2026, By The Business Research Company

Denosumab Global Market Report

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Macadamia Global Market Report

https://www.thebusinessresearchcompany.com/report/macadamia-global-market-report

Capecitabine Global Market Report

https://www.thebusinessresearchcompany.com/report/capecitabine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795